Neurocrine Biosciences | NBIX - Cost Of Sales


Neurocrine Biosciences reported $17.6M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Exelixis USD 26.48M 7.91M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Repligen USD 94.08M 5.79M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025
Xoma 116K 112.7K Jun/2024